Yes, targeting the RISC pathway offers promising therapeutic potential. For instance, synthetic siRNAs can be designed to specifically silence genes that are overexpressed in certain pediatric diseases. This approach is being explored in clinical trials for treating various conditions, including genetic disorders and cancers. Moreover, the development of miRNA-based therapies is an emerging field that holds promise for treating pediatric diseases by restoring normal gene expression patterns.
